A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

Trial Profile

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Acronyms HIJAK
  • Most Recent Events

    • 06 Dec 2016 Results assessing efficacy and safety presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Jan 2018.
    • 01 Sep 2015 Planned End Date changed from 1 Jun 2019 to 1 May 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top